The value of 68Ga-DOTATATE PET/CT in diagnosis and management of neuroendocrine tumors compared to current FDA approved imaging modalities: a review of literature

American Journal of Nuclear Medicine and Molecular Imaging

David Ranganathan¹  Sanjay Thamake¹  Izabela Tworowska¹  Alireza Mojtahedi¹  Ebrahim S Delpassand¹ 

关键词: Gallium 68;    neuroendocrine tumors;    DOTATATE;    positron emission tomography;    hybrid imaging;   

DOI  :  

学科分类：过敏症与临床免疫学

来源: e-Century Publishing Corporation

【 摘 要 】

Neuroendocrine tumors (NETs) are rare group of neoplasms arising from nervous and endocrine systems. Somatostatin analogue imaging is a functional imaging modality of choice for evaluating the NETs. Recent availability of positron emitting radioisotope labeled somatostatin analogues to image neuroendocrine cancers, has raised the interests to use this new imaging modality in management of patients with NETs. ⁶⁸Ga-DOTATATE PET/CT has demonstrated superiority in lesion detection compared to Octreoscan, MIBG scintigraphy and MRI. In this article, we reviewed the published studies evaluating the role of ⁶⁸Ga-DOTATATE PET in diagnosis and management of patients with neuroendocrine tumors and comparing it to current FDA approved imaging modalities including Octreoscan, MIBG scintigraphy, ¹⁸F FDG PET/CT, CT and MRI.

【 授权许可】

Unknown